WEBINAR REPORT
A discussion on
connective tissue disease Dr Ajesh Maharaj, consultant physician/ consultant rheumatologist at Life Westville Hospital in KwaZulu-Natal recently presented an informative webinar on connective tissue disease. This was sponsored by Thermo Fisher Scientific and hosted by Medical Chronicle. The following article is based on his presentation.
D
R AJESH FOCUSSED on the following in his presentation: • Understand the classification criteria of systemic lupus erythematosus (SLE) • Clinical features • Assessment • Latest treatment approaches. SYSTEMIC LUPUS ERYTHEMATOSUS: 1982 CLASSIFICATION CRITERIA If we look at the systemic lupus erythematosus: 1982 classification criteria definitions, we see 11 criteria: • Malar rash. Fixed erythema, flat or raised, sparing the nasolabial folds • Discoid rash. Raised patches, adherent keratotic scaling, follicular plugging; older lesions may cause scarring • Photosensitivity. Skin rash from sunlight • Oral or nasopharyngeal ulcers, usually painless • Arthritis. Nonerosive, inflammatory in two or more peripheral joints • Serositis. Pleuritis or pericarditis. • Renal disorder. Persistent proteinuria or cellular casts • Neurologic disorder. Seizures or psychosis • Hematologic haemolytic anaemia, leukopenia (<4 000/mm3), lymphopenia (<1 500/mm³), or thrombocytopenia (<100 00/mm3) • Immunologic disorder. Antibodies to double-stranded deoxyribonucleic acid (dsDNA) or SM or positive antiphospholipid antibodies (IgG or IgM antibodies, lupus anticoagulant, or falsepositive serologic test positive serologic test for syphilis) • Antinuclear antibody test: Positive. The Systemic Lupus International Collaborating Clinics (SLICC) classification had 17 criteria. According to the SLICC rule for the classification of SLE, the patient must satisfy at least four criteria. CLASSIFICATION OF NEPHRITIS Systemic lupus erythematosus: classification of nephritis • Normal glomeruli • a) Nil by all techniques • b) Normal by light but deposits on electron microscopy or immunofluorescence • Mesangial glomerulonephritis • Focal glomerulonephritis • Diffuse glomerulonephritis (this is the worst type) • Diffuse membranous glomerulonephritis • Advanced sclerosing glomerulonephritis. Systemic lupus erythematosus: nervous
system manifestations: • Seizures • Ataxia • Headache • Rigidity, tremor • Stroke syndromes • Chorea • Subarachnoid haemorrhage • Hemiballismus • Transverse myelitis • Coma • Multiple sclerosis-like disorder • Dementia • Optic neuritis • Psychiatric disorders • Aseptic meningitis • Peripheral neuropathy • Cranial neuropathy • Mononeuritis multiplex • Guillain-Barré syndrome. If antinuclear factor ANF tests positive, please request extractable nuclear antigen antibodies (ENAs) panel. DRUG-INDUCED LUPUS Definite drug associations are: • Hydralazine • Procainamide • Minocycline • Chlorpromazine • Isoniazid • Penicillamine • Methyldopa • Interferon-alpha. Possible drug associations include: • Anticonvulsants • Quinidine • Propylthiouracil • Sulfonamides • Lithium • Beta-blockers • Nitrofurantoin • Sulfasalazine. Clinicians ordering the anti-nuclear antibodies (ANA) test should be aware of the test's low-positive predictive value in settings with a low prevalence of rheumatic disease, particularly among older patients. BASELINE INVESTIGATIONS FOR SLE • Full blood count • Urea and electrolytes • Complement (C3 & C4) test • ANF with ENAs/ dsDNA/ anti Smith Antibodies • Antiphospholipid antibodies/ Anticardiolipin antibodies • Lupus anticoagulant • Urine for microscopy and sensitivity/
Dr Ajesh Maharaj MB.BS; (India); H.Dip.Int.Med.(SA); FCP(SA); Cert in Rheumatology(SA); FACR; Ph.D. (Universiteit van Amsterdam)
To watch a replay of the webinar and still earn your CPD point, go to https://bit.ly/3kW6tMe
urinary creatinine: protein ration • 24-hour urinary protein with creatinine clearance.
• Constitutional symptoms • Rash: body surface area (BSA) <9% • Platelets; 50-100 x 109/L.
PRELIMINARY CLASSIFICATION CRITERIA FOR ANTIPHOSPHOLIPID SYNDROME • APS is present if more than one clinical and one lab criteria met • Vascular thrombosis • > One arterial, venous, or small-vessel thrombosis and • Thrombosis confirmed by imaging or Doppler or histopathology and • Without evidence of inflammation in vessel wall on histpathologic confirmation • Pregnancy morbidity • > One foetal death > 10th week gestation or • > One premature birth > 34th week with preeclampsia or placental insufficiency or • > Three consecutive spontaneous abortions • < 10th week gestation • Laboratory criteria • Anticardiolipin antibody IgG or IgM present medium or high titers >two times at least six weeks apart or • Lupus anticoagulant present > two times at least six weeks apart.
Moderate disease: • Rheumatoid arthritis like arthritis • Rash: 9%-18% BSA • Cutaneous vasculitis <18% BSA • Platelets; 20-50x 109/L • Serositis.
ANTIPHOSPHOLIPID ANTIBODY SYNDROME Clinical manifestations of this include: • Arterial thrombosis • Venous thrombosis • Valvular abnormalities • Pregnancy loss and infertility • Livedo reticularis • Cerebrovascular thrombosis • Chorea. Antiphospholipid antibody syndrome: tests • Partial thromboplastin time (PTT) • Lupus anticoagulant • Anticardiolipin antibodies by ELISA • Anti-B2-glycoprotein one antibody • False-positive biologic test for syphilis • Russell viper venom test • Platelet count • Antinuclear and anti-DNA antibodies. Ancillary investigations • Chest x-ray • Electrocardiogram. Assessment of SLE Mild disease:
SEVERE DISEASE • Major organ threatening disease: nephritis, cerebritis, myelitis, pneumonitis, mesenteric vasculitis • Severe thrombocytopenia with platelets <20 x 109/L • Thrombotic thrombocytopenic purpuralike disease • Acute haemophagocytic syndrome. TREATMENT OF NON-RENAL SLE Generally, chloroquine is accepted as treatment for all forms of mild, moderate, or severe disease. You can use systemic steroids such as glucocorticoids and prednisone, and we generally use a combination of chloroquine and prednisone. Prednisone is generally started at 1mg per kilogram depending on what the severity of the disease is, especially if they have kidney involvement, brain involvement, lung involvement or heart involvement, it’s generally pulse glucocorticoids systemic corticosteroids and then once we get them under control, we can use methotrexate as a steroid-sparing agent. In patients with moderate to severe disease we use belimumab, which is not available in South Africa, but it is available on Section 21 if it is needed in patients. We don’t have calcineurin inhibitors, but we have mycophenolate mofetil, which we can use for moderate to severe disease. In patients with severe lupus, we can use cyclophosphamide generally administered as a pulse cyclophosphamide, as a monthly dose and if everything else fails in a patient with lupus after having put them on chloroquine, prednisone, azathioprine, methotrexate, mycophenolate mofetil and cyclophosphamide we then use rituximab which is a biologic for the treatment of lupus and is registered in South Africa for the treatment of systemic lupus erythematosus. This is generally reserved as a last treatment option, and it is done by a rheumatologist. MEDICAL CHRONICLE | May 2022 37
